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example in the special issues on
biotech in China, Russia and
Singapore [4–6]),several aspects
of antibodies as therapeutics are
addressed in this issue of BTJ.
Ruuls et al. review a new class of
antibody therapeutics: the age 
of the Umabs [7]. Zhou et al. re-
view modern production tech-
nologies [8] and Garidel et al. re-
port on a rapid, sensitive and
economical assessment of mon-
oclonal antibody conformational
stability by intrinsic tryptophan
fluorescence spectroscopy [9].
These three papers are a good
attempt to get quick insights into
the challenge of antibody pro-
cessing.
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Editorial: Antibodies and other
biopharmaceuticals
The contribution of biotech-
nology will be to optimize pro-
duction systems and even create
new processes. This will not
happen instantaneously, since
processes are in place and a safe
replacement is slow and re-
quests additional clinical trials.
Therefore,we will observe an in-
cremental change within the
next years. Eventually for new
products we may observe a rad-
ical change in production tech-
nologies, using unit operations
which have been around since a 
long time
but will be re-
fined for the
needs of bio-
pharmaceutical production. Re-
combinant antibodies may be
the first candidates for which we
will see the implementation of
these technologies.
In the area of antibody man-
ufacturing we also have ob-
served a massive improvement
of cell line productivity. They
have been boosted to up to 10g/L
and downstream processing
cannot keep pace with this de-
velopment. Although in down-
stream processing the constant
improvement of chromatogra-
phy material and membrane fil-
ters enable now productivities,
which would
have been
unthinkable
just a decade
ago.
Whereas
Biotechnology
Journal 
has often
highlighted
the rise of
biopharma-
ceuticals (for 
Biopharmaceuticals are not
any longer in their infancy,since
their uprise in the nineties they
are grown ups now.The general
public and even scientists work-
ing in biological disciplines may
not realize that in the Western
world at least 20% of pharma-
ceuticals are already of biologi-
cal origin. What was a big inno-
vation 30 years ago [1] has be-
come reality [2].When question-
ing why we have already 20-30%
of biopharmaceuticals a simple
answer is: they are efficacious,
potent and
safe. Only one
of all approved
biopharma-
ceutical needed to be removed
from the market and biophar-
maceutical companies thrive on
their patents [3]. Biopharma-
ceuticals meet the therapeutic
needs.
However, despite the clinical
success of biopharmaceuticals,
our society is facing a dilemma.
Biopharmaceuticals may blow
up the healthcare budget, as
some of these drugs cost up to
35 000 US $ per therapy. So the
social need to restrict health
care expense is in conflict with
the success of these new prod-
ucts.
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Biopharmaceuticals are efficacious,
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